Table 3.
Association between genotypes of NQO2 tri-allelic polymorphism and risk of breast cancer subtypes.
| Genotype | Control (N = 1,655, %)* | Luminal-A case (N = 423, %)* | Luminal-B case (N = 338, %)* | HER2-enriched case (N = 113, %)* | Triple-negative case (N = 269, %)* | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| I-29/I-29 | 1,024 | 61.9 | 302 | 71.4 | 233 | 68.9 | 74 | 65.5 | 169 | 62.8 |
| I-29/D | 568 | 34.3 | 108 | 25.5 | 93 | 27.5 | 34 | 30.1 | 94 | 34.9 |
| D/D | 63 | 3.8 | 13 | 3.1 | 12 | 3.6 | 5 | 4.4 | 6 | 2.2 |
| P | <0.001ζ | 0.001¶ | 0.045ζ | 0.014¶ | 0.64ζ | 0.44¶ | 0.43ζ | 0.76¶ | ||
| Dominant model OR (95% CI)¶ | 1.54 (1.22–1.94) | 1.37 (1.06–1.76) | 1.16 (0.78–1.75) | 1.04 (0.80–1.36) | ||||||
*
individuals with the I-16 allele were excluded from this analysis.
ζ
unadjusted p-value of two-sided χ2 test.
¶
OR and 95%CI calculated by logistic regression, adjusted for age, age at menarche, menopause status, and body mass index in the dominant model (I-29/I-29 vs. I-29/D+D/D).